Latest News
Press background on Venus Remedies
Company profile
Venus Remedies, headquartered in Panchkula, Haryana (India), is among the 10 leading fixed-dosage injectable manufacturers in the world. The company has three manufacturing units, in Panchkula, Baddi (both India) and Werne (Germany) and 11 overseas marketing offices, including a presence in the US and Germany. The manufacturing units are certified for ISO 9001, ISO 14001, ISO 18001 and OHSAS. The company has also been approved by EUROPEAN-GMP, WHO-GMP, Latin American GMP (INVIMA), Ukrainian GMP, Zimbabwe GMP, Uganda GMP, Syrian GMP, Columbian GMP, Kenya GMP, Yemen GMP, Saudi Arabian GMP and Iranian GMP, among others. Venus Remedies has been ranked 107th in Asia (source: Bio Spectrum Asia) and among the 500 largest pharmaceutical manufacturing companies in the world (source: Plimsoll Worldwide Business Intelligence Report). Venus has won over 102 patents for its innovative research products worldwide. The company has presence in 60 countries and covers more than 75 products.
 Recent press releases
Budget Expectation from Mr Pawan Chaudhary, CMD, Venus Remedies

Quote of Mr Pawan Chaudhary, Chairman and Managing Director, Venus Remedies on his expectations from the 2015-16 Union Budget:
The Union Finance Minister should take his government’s “Make in India” campaign to the next level by taking steps to boost... (more)
Venus Remedies Bags Indian Patent for Vancoplus

The novel antibiotic adjuvant entity is highly effective against drug-resistant infections, different resistance mechanisms which no other existing therapeutic options available in the market are able to tackle
Vancoplus projected to cater to a market of Rs 214 crore in India by... (more)
Venus Strengthens Portfolio in Swiss Market with Marketing Authorisation for Meropenem

Gets approval from Swiss drug authority Swissmedic through its German subsidiary Venus Pharma GmbH for meropenem 500 mg, 1 g injections
With plans to launch the product early next year through its partner Swiss Pharma GmbH Zurich, Venus eyes 10% share in Switzerland’s mero... (more)
Venus Forays Into Singapore’s Topical Pain Management Market with Marketing Approval, Patent for Trois

Company holding talks with various pharmaceutical firms for tie-ups
Trois has a huge potential in Singapore, where 10% people are diagnosed with arthritis, 73.4% of the office workers suffer from musculoskeletal disorders and 20% of the population above the age of 65 suffers fro... (more)
Venus Ties Up with Mylan for Marketing Meropenem in Three European Countries

The distribution-cum-outlicensing agreement between Venus Pharma GmbH, Germany and Mylan will enable Venus Remedies to market meropenem in Denmark, Sweden and Finland for five years
While the drug will be manufactured at Venus Remedies’ Baddi facility, batch release and lo... (more)
Venus Remedies Ties up With Teva for Anti-Cancer Drug to Enter Canadian Market for First Time

Venus will initially manufacture the drug at the Venus Medicine Research Centre, its research unit, for assisting Teva in registrations, after which the company will use its manufacturing capabilities to support Teva in enhancing business from this drug in Canada
Wh... (more)
Venus Bags its First Swiss Marketing Authorisation for Gemcitabine

Being among the first few pharma firms to receive marketing authorisation for Gemcitabine, an oncology drug, and the first Indian company to get marketing approval for this product from Switzerland, Venus Remedies enjoys a competitive edge over other players and is all set to capture a su... (more)